Alendronate sodium is a Small Molecule owned by Merck & Co, and is involved in 27 clinical trials, of which 25 were completed, and 2 are ongoing.

Alendronate inhibits farnesyl pyrophosphate (FPP) synthase. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids which are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This inhibits osteoclast activity and reduces bone resorption and turnover. It reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass in postmenopausal women.

The revenue for Alendronate sodium is expected to reach a total of $2.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Alendronate sodium NPV Report.

Alendronate sodium is currently owned by Merck & Co. Organon is the other company associated in development or marketing of Alendronate sodium.

Alendronate sodium Overview

Alendronate sodium (Fosamax/ Adronat/ Fosamac// Bonalon/ Dronal/ Alendros/ Alendronate/ Fosalan) is an antihypocalcemic agent, anti-osteoporotic agent. It is formulated in the form of tablets, solution and jelly for oral administration and solution for intravenous route of administration. It is indicated for the treatment of osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, glucocorticoid-induced osteoporosis and paget's disease of bone in men and women and hip fractures.

Alendronate sodium was under development for the treatment of osteogenesis imperfecta in pediatric patients (4 years of age and older).

Organon Overview

Organon is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It works in collaboration with pharmaceutical and biopharmaceutical companies to commercialize its products. Organon is headquartered in Jersey City, New Jersey, the US.

The company reported revenues of (US Dollars) US$6,304 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.5% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 42.1% in FY2020. In FY2021, the company recorded a net margin of 21.4%, compared to a net margin of 33.1% in FY2020. The company reported revenues of US$1,537 million for the third quarter ended September 2022, a decrease of 3% over the previous quarter.

Quick View – Alendronate sodium

Report Segments
  • Innovator (NME)
Drug Name
  • Alendronate sodium
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Musculoskeletal Disorders
  • Women’s Health
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.